- Home
- REGN vs BP Comparison
REGN vs BP Comparison
Compare REGN & BP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- BP
- Stock Information
- Founded
- REGN 1988
- BP 1889
- Country
- REGN United States
- BP United Kingdom
- Employees
- REGN N/A
- BP N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- BP Integrated oil Companies
- Sector
- REGN Health Care
- BP Energy
- Exchange
- REGN Nasdaq
- BP Nasdaq
- Market Cap
- REGN 63.4B
- BP 75.1B
- IPO Year
- REGN 1991
- BP N/A
- Fundamental
- Price
- REGN $490.28
- BP $29.09
- Analyst Decision
- REGN Buy
- BP Hold
- Analyst Count
- REGN 23
- BP 12
- Target Price
- REGN $891.17
- BP $33.26
- AVG Volume (30 Days)
- REGN 1.5M
- BP 10.6M
- Earning Date
- REGN 04-29-2025
- BP 04-29-2025
- Dividend Yield
- REGN 0.36%
- BP 6.53%
- EPS Growth
- REGN 16.49
- BP N/A
- EPS
- REGN 39.43
- BP N/A
- Revenue
- REGN $14,085,700,000.00
- BP $185,408,000,000.00
- Revenue This Year
- REGN N/A
- BP N/A
- Revenue Next Year
- REGN $6.97
- BP $1.53
- P/E Ratio
- REGN $12.43
- BP N/A
- Revenue Growth
- REGN 7.52
- BP N/A
- 52 Week Low
- REGN $485.00
- BP $25.23
- 52 Week High
- REGN $1,211.20
- BP $37.58
- Technical
- Relative Strength Index (RSI)
- REGN 32.32
- BP 48.05
- Support Level
- REGN $590.15
- BP $28.85
- Resistance Level
- REGN $608.17
- BP $29.30
- Average True Range (ATR)
- REGN 18.79
- BP 0.43
- MACD
- REGN -3.82
- BP 0.00
- Stochastic Oscillator
- REGN 3.98
- BP 28.22
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About BP BP p.l.c.
BP is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2024, it produced 1.2 million barrels of liquids and 6.9 billion cubic feet of natural gas per day. At the end of 2023, reserves stood at 6.8 billion barrels of oil equivalent, 55% of which are liquids. The company operates refineries with a capacity of 1.6 million barrels of oil per day.